SHIFA BIOMEDICAL CORPORATION

Patent Applications and Registrations

Patent applications and USPTO patent grants for SHIFA BIOMEDICAL CORPORATION.The latest application filed is for "anti-proprotein convertase subtilisin kexin type 9 (anti-pcsk9) nano-formulation of compounds and methods of using the same".

Company Profile

8.10.9

SHIFA BIOMEDICAL CORPORATION - Malvern PA US
Shifa Biomedical Corporation - Malvem PA US

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Anti-proprotein Convertase Subtilisin Kexin Type 9 (anti-pcsk9) Nano-formulation Of Compounds And Methods Of Using The Same App 20220031665 - Mousa; Shaker A. ; et al.	2022-02-03
Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases Grant 10,947,220 - Abdel-Meguid , et al. March 16, 2	2021-03-16
Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases Grant 10,899,748 - Abdel-Meguid , et al. January 26, 2	2021-01-26
Anti-Proprotein Convertase Subtilisin Kexin Type 9 (Anti-PCSK9) Compounds and Methods of Using the Same in the Treatment and/or App 20200262822 - Abdel-Meguid; Sherin Salaheldin ; et al.	2020-08-20
Anti-Proprotein Convertase Subtilisin Kexin Type 9 (Anti-PCSK9) Compounds and Methods of Using the Same in the Treatment and/or App 20190270729 - Abdel-Meguid; Sherin Salaheldin ; et al.	2019-09-05
Anti-endothelial lipase compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases Grant 10,259,804 - Elshourbagy , et al.	2019-04-16
Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases Grant 10,131,637 - Abdel-Meguid , et al. November 20, 2	2018-11-20
Anti-pcsk9 Compounds And Methods For The Treatment And/or Prevention Of Cardiovascular Diseases App 20180079730 - Abdel-Meguid; Sherin Salaheldin ; et al.	2018-03-22
Anti-endothelial Lipase Compounds And Methods Of Using The Same In The Treatment And/or Prevention Of Cardiovascular Diseases App 20170305887 - ELSHOURBAGY; Nabil ; et al.	2017-10-26
Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases Grant 9,682,085 - Abdel-Meguid , et al. June 20, 2	2017-06-20
Anti-proprotein Convertase Subtilisin Kexin Type 9 (anti-pcsk9) Compounds And Methods Of Using The Same In The Treatment And/or Prevention Of Cardiovascular Diseases App 20160256467 - Abdel-Meguid; Sherin Salaheldin ; et al.	2016-09-08
Functionalized Furan-2-sulfonamides Exhibiting Endothelial Lipase Inhibition App 20160257672 - Abou-Gharbia; Magid ; et al.	2016-09-08
Anti-proprotein Convertase Subtilisin Kexin Type 9 (anti-pcsk9) Compounds And Methods Of Using The Same In The Treatemnt And/or Prevention Of Cardiovascular Diseases App 20150374710 - Abdel-Meguid; Sherin Salaheldin ; et al.	2015-12-31
Anti-pcsk9 Compounds And Methods For The Treatment And/or Prevention Of Cardiovascular Diseases App 20150376139 - Abdel-Meguid; Sherin Salaheldin ; et al.	2015-12-31

Company Registrations

NCAGE Code	7P8Y4	SHIFA BIOMEDICAL CORPORATION
NCAGE Code	47WR5	SHIFA BIOMEDICAL CORPORATION
CAGE Code	47WR5	SHIFA BIOMEDICAL CORPORATION
CAGE Code	7P8Y4	SHIFA BIOMEDICAL CORPORATION
S.A.M. Registration	47WR5 [192526221]	SHIFA BIOMEDICAL CORPORATION

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.